On December 31, 2024, Vanguard Group Inc made a strategic decision to reduce its holdings in Marinus Pharmaceuticals Inc (MRNS) by 206,197 shares. This transact
PR NewswireNEW YORK, Jan. 15, 2025
NEW YORK, Jan. 15, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co
PR NewswireNEW YORK, Jan. 9, 2025
NEW YORK, Jan. 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp
NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o
PR NewswireNEW YORK, Jan. 6, 2025
NEW YORK, Jan. 6, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp
PR NewswireNEW YORK, Jan. 3, 2025
NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp
NEW YORK, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o
Immedica Pharma AB (Immedica), a leading global rare disease company, and [url="]Marinus Pharmaceuticals, Inc.[/url] (Nasdaq: MRNS), a pharmaceutical company c
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Thursday.
Following the market opening Thursday, the Dow traded do...
Penny stocks are defined by the Securities and Exchange Commission (SEC) as stocks that trade for less than $5 per share. They exhibit high price volatility due to their low pricing.
LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.